erythromycin has been researched along with 14-hydroxyclarithromycin in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.00) | 18.7374 |
| 1990's | 16 (80.00) | 18.2507 |
| 2000's | 1 (5.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, HY; Maskell, JP; Powell, M | 1 |
| Azoulay-Dupuis, E; Bédos, JP; Pocidalo, JJ; Vallée, E; Veber, B | 1 |
| Cavanaugh, JC; Chu, S; Locke, C; Park, Y; Wilson, DS | 1 |
| Hoffman, BM; Olsson-Liljequist, B | 1 |
| Dabernat, H; Delmas, C; Fourtillan, JB; Girault, J; Lareng, MB; Seguy, M | 1 |
| Azoulay-Dupuis, E; Bergogne-Bérézin, E; Pocidalo, JJ; Swanson, R; Vallée, E | 1 |
| Andrews, JM; Ashby, JP; Logan, MN; Wise, R | 1 |
| Chen, HY; Powell, M; Weinhardt, B; Williams, JD | 1 |
| Howell, AW; Jorgensen, JH; Maher, LA | 1 |
| Gu, JW; Neu, HC; Scully, BE | 1 |
| Barry, AL; Fuchs, PC; Pfaller, MA | 1 |
| Chu, SY; Sennello, LT; Sonders, RC | 1 |
| Clement, JJ; Hardy, DJ; Marsh, K; Rode, RA; Shipkowitz, NL; Swanson, RN | 1 |
| Barrett, MS; Erwin, ME; Jones, RN | 1 |
| Adachi, T; Iwasaki, H; Kamiya, N; Morimoto, S; Watanabe, Y | 1 |
| Fernandes, PB; Freiberg, L; Ramer, N; Rode, RA | 1 |
| Adachi, T; Kondoh, H; Morimoto, S; Nagate, T; Sota, K; Watanabe, Y | 1 |
| Cederbrant, G; Kahlmeter, G; Kamme, C; Schalén, C | 1 |
| Beyer, J; Capobianco, J; Flamm, R; Goldman, RC; Zakula, D | 1 |
| Garvin, CG; Martin, SJ; McBurney, CR; Sahloff, EG | 1 |
1 trial(s) available for erythromycin and 14-hydroxyclarithromycin
| Article | Year |
|---|---|
Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial.
Topics: Absorption; Administration, Oral; Adult; Biological Availability; Chromatography, High Pressure Liquid; Clarithromycin; Erythromycin; Fasting; Food; Humans; Male | 1992 |
19 other study(ies) available for erythromycin and 14-hydroxyclarithromycin
| Article | Year |
|---|---|
Protective efficacy of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae in a murine septicaemia model.
Topics: Animals; Bacteremia; Clarithromycin; Disease Models, Animal; Drug Synergism; Erythromycin; Female; Haemophilus Infections; Haemophilus influenzae; Mice; Mice, Inbred BALB C | 1992 |
Individual efficacy of clarithromycin (A-56268) and its major human metabolite 14-hydroxy clarithromycin (A-62671) in experimental pneumococcal pneumonia in the mouse.
Topics: Animals; Clarithromycin; Erythromycin; Female; Lung; Mice; Microbial Sensitivity Tests; Pneumonia, Pneumococcal | 1992 |
In-vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae.
Topics: Clarithromycin; Drug Therapy, Combination; Erythromycin; Haemophilus influenzae; Microbial Sensitivity Tests | 1991 |
The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests.
Topics: Clarithromycin; Drug Therapy, Combination; Erythromycin; Female; Haemophilus influenzae; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Serum Bactericidal Test; Species Specificity | 1991 |
Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Erythromycin; Female; Haemophilus Infections; Haemophilus influenzae; Lung Diseases; Mice; Mice, Inbred C57BL | 1991 |
The in-vitro and disc susceptibility testing of clarithromycin and its 14-hydroxy metabolite.
Topics: Bacteria; Blood Proteins; Clarithromycin; Drug Evaluation, Preclinical; Drug Therapy, Combination; Erythromycin; Microbial Sensitivity Tests; Protein Binding | 1991 |
In-vitro cidal activity of clarithromycin and its 14-hydroxy metabolite (A-62671) against Haemophilus influenzae.
Topics: Clarithromycin; Drug Evaluation, Preclinical; Drug Therapy, Combination; Erythromycin; Haemophilus influenzae; Microbial Sensitivity Tests; Time Factors | 1991 |
Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae.
Topics: Clarithromycin; Drug Resistance, Microbial; Erythromycin; Haemophilus influenzae; Humans; Microbial Sensitivity Tests | 1991 |
Bactericidal activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae and streptococcal pathogens.
Topics: Administration, Oral; Clarithromycin; Erythromycin; Haemophilus influenzae; Humans; Serum Bactericidal Test; Streptococcus; Streptococcus pneumoniae; Streptococcus pyogenes | 1991 |
Susceptibility of Haemophilus influenzae to clarithromycin alone and in combination with its 14-hydroxy metabolite.
Topics: Clarithromycin; Drug Therapy, Combination; Erythromycin; Haemophilus influenzae; Microbial Sensitivity Tests | 1991 |
Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection.
Topics: Chromatography, High Pressure Liquid; Clarithromycin; Electrochemistry; Erythromycin; Humans | 1991 |
Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.
Topics: Animals; Clarithromycin; Drug Synergism; Erythromycin; Female; Gerbillinae; Haemophilus Infections; Haemophilus influenzae; Microbial Sensitivity Tests; Otitis Media | 1990 |
In vitro activity of clarithromycin (TE-031, A-67268) and 14OH-clarithromycin alone and in combination against Legionella species.
Topics: Clarithromycin; Drug Therapy, Combination; Erythromycin; Legionella; Microbial Sensitivity Tests | 1990 |
Crystal and molecular structure of (14R)-14-hydroxy-6-O-methylerythromycin A.
Topics: Clarithromycin; Crystallization; Erythromycin; Molecular Structure; X-Ray Diffraction | 1989 |
Bioassay for A-56268 (TE-031) and identification of its major metabolite, 14-hydroxy-6-O-methyl erythromycin.
Topics: Biological Assay; Chromatography, High Pressure Liquid; Clarithromycin; Erythromycin; Humans; Micrococcus | 1988 |
14-Hydroxy-6-O-methylerythromycins A, active metabolites of 6-O-methylerythromycin A in human.
Topics: Chemical Phenomena; Chemistry; Clarithromycin; Erythromycin; Humans; Molecular Conformation | 1988 |
Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori.
Topics: Amoxicillin; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Erythromycin; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Metronidazole; Microbial Sensitivity Tests; Omeprazole | 1994 |
Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes.
Topics: Centrifugation, Density Gradient; Clarithromycin; Erythromycin; Escherichia coli; Helicobacter pylori; Indicators and Reagents; Ribosomes | 1994 |
The activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Clarithromycin; Colony Count, Microbial; Drug Combinations; Drug Resistance, Multiple; Erythromycin; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Streptococcus pneumoniae | 2001 |